The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Prognostic factors for early-stage CTCL
Evangelina Papadavid, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, gives an overview of the management of early-stage cutaneous T-cell lymphoma (CTCL), commenting on the role of prognostic factors, in particular the significance of plaques in early disease, and highlighting the Prospective Cutaneous Lymphoma International Prognostic Indices (PROCLIPI) trial. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
